Abstract
Single-agent chemotherapy (CT) is a valuable option for patients with advanced breast cancer (ABC) and weekly oral VNR is one of the recommended agents. Metronomic VNR increases patient’s exposure to the drug while improving safety. In early studies, minimal toxicity and promising efficacy were observed with metronomic VNR 50 mg thrice weekly (tw). We randomized patients with ABC to receive either metronomic or weekly oral first-line VNR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
